FANJ
AGIO icon

Financial Architects (New Jersey)’s Agios Pharmaceuticals AGIO Stock Holding History

Financial Architects (New Jersey)’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200
Closed -$9K – 1409
2018
Q4 		$9K Buy
+200
New +$12.3K ﹤0.01% 1008

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Financial Architects (New Jersey)'s AGIO Position: Q1 2017 in Review

Financial Architects (New Jersey) sold out of Agios Pharmaceuticals (AGIO) in Q1 2017, closing a stake of 1,000 shares — an estimated $42K sold.

Financial Architects (New Jersey) first reported a position in AGIO in Q4 2014 and held it in 7 quarters. The position peaked at $224K in Q2 2015. 156 funds tracked by Wall St. Rank hold AGIO as of Q1 2017.

  • Financial Architects (New Jersey) reported no remaining Agios Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 1,000 Agios Pharmaceuticals shares in Q1 2017, an estimated $42K.
  • Financial Architects (New Jersey) first reported a position in Agios Pharmaceuticals in Q4 2014 and held it in 7 quarters.
  • Financial Architects (New Jersey)'s Agios Pharmaceuticals position peaked at $224K in Q2 2015.
  • 156 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2017.

Based on Financial Architects (New Jersey)'s 13F filing for Q1 2017, filed 26 Apr 2017.